NCCN 2022 Pharmacy Updates: A Webinar Series
The availability of new therapeutic options and emergence of novel therapies continues to dramatically impact the oncology landscape. The rapid integration of these agents into treatment for various tumor types can be challenging for clinicians. Pharmacists are critical to educating the interprofessional oncology care team about the actions and potential adverse events associated with new and existing therapeutic options. Pharmacists also have an important role in patient education, as well as subsequent monitoring and management of treatment-related toxicities.
This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician assistants and other health care professionals who manage patients with cancer.
The goal of this program is to ensure that pharmacists, physicians, nurses, nurse practitioners, physician assistants, and other members of the interprofessional oncology care team who manage patients with cancer have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer
- Communicate the importance of a multidisciplinary approach and improve the collaborative performance of the interprofessional oncology care team in the management of patients with cancer
All live webinars in this series have concluded. The recorded webcasts are listed below.
- Understanding the Place in Therapy for an Oral LHRH Antagonist as a Treatment Option in Prostate Cancer (presented on January 28, 2022, by Amy Schneider, PharmD, BCOP, Moffitt Cancer Center)
- Not Just a Band-Aid: The Impact of Chemotherapy Dose Banding in Infants (presented on February 25, 2022, by Alexis Kuhn, PharmD, BCOP, Mayo Clinic Cancer Center)
- Crossroads of Exercise and Chemotherapy (presented on March 10, 2022, by Brianna Archambeau, PharmD, BCOP, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute)
- Mycosis Fungoides and Sézary Syndrome: Overview of Systemic Therapy (presented on April 29, 2022, by Andréa LeVoir, PharmD, BCOP, Memorial Sloan Kettering Cancer Center)
- CAR-T Therapy in Multiple Myeloma (presented on May 20, 2022, by Jessica Loborec, PharmD, BCOP, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute)
- Updates in the Management of Unresectable or Metastatic Cutaneous Melanoma (presented on June 30, 2022, by Bethany Withycombe, PharmD, BCOP, Moffitt Cancer Center)
- Navigating Advances in Targeted Therapies for Advanced Esophageal, Esophagogastric Junction (EGJ) and Gastric Cancers (presented on August 8, 2022, by Van Nguyen, PharmD, BCOP, The University of Texas MD Anderson Cancer Center)
- The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia (presented on August 24, 2022, by Suzanne Gettys, PharmD, BCOP, The University of Texas MD Anderson Cancer Center)
- Updates in the Management of Indolent Non-Hodgkin Lymphomas (presented on October 7, 2022, by Phuong Cham Nguyen, PharmD, BCOP, BCIDP, UCSF Helen Diller Family Comprehensive Cancer Center)
- Novel Therapies for the Treatment of Metastatic Breast Cancer (presented on October 27, 2022, by Melissa Armitage, PharmD, BCOP, Moffitt Cancer Center)
- Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer (presented on November 22, 2022, by Chris Selby, PharmD, BCOP, UT Southwestern Simmons Comprehensive Cancer Center)
- Updates in Older Adult Oncology (presented on December 21, 2022, by Jerline Hsin, PharmD, BCPS, BCOP, City of Hope National Medical Center)
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Full disclosure of faculty relationships will be made prior to the activity.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates each live activity in this series for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates each educational activity in this series for a maximum of 1.0 contact hour.
NCCN designates each application-based continuing education activity in this series for 1.0 contact hour (0.10 CEUs) of continuing education credit.
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Each activity in this series is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.
To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.